Acura Pharmaceuticals, Inc.
ACUROTCHealthcare● Active
$0.00
+$0.00(+150.00%)
Market Cap$33001
P/E Ratio—
52W High$0.01
52W Low$0.0001
Acura Pharmaceuticals, Inc. (ACUR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ACUR · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2021Report Date: Dec 31, 2021EPS Actual
$0.00
Revenue
$0.00B
Fiscal Period
Q4 FY2021
FY ends December
Report Date
Dec 31, 2021
After Market Close
ACUR reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2023 | Aug 7, 2023 | — | — | — | — | $0.00B | — |
| ◌ Q2 FY2023 | May 19, 2023 | — | — | — | — | $0.00B | — |
| ◌ Q1 FY2023 | Mar 3, 2023 | — | — | — | — | $0.00B | — |
| ◌ Q3 FY2022 | Jul 4, 2022 | — | — | — | — | $0.00B | — |
| — Q4 FY2021 | Dec 31, 2021 | — | $0.00 | — | $0.00B | — | — |
| — Q4 FY2021 | Nov 15, 2021 | — | -$0.00 | — | $0.00B | $0.00B | +193.5% |
| — Q3 FY2021 | Aug 16, 2021 | — | -$0.01 | — | $0.00B | — | — |
| — Q2 FY2021 | May 18, 2021 | — | -$0.01 | — | $0.00B | — | — |
Q3 FY2023
Aug 7, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
May 19, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 3, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2022
Jul 4, 2022
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2021
Dec 31, 2021
EPS Actual
$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2021
Nov 15, 2021
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2021
Aug 16, 2021
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2021
May 18, 2021
EPS Actual
-$0.01
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 6 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 6 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 13 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 13 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 14 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2021 | Dec 31, 2021 | — | $0.50 | $0.50 | -0.79% |
| — Q4 FY2021 | Nov 15, 2021 | — | $0.56 | $0.56 | -0.46% |
| — Q3 FY2021 | Aug 16, 2021 | — | $0.64 | $0.60 | -6.24% |
| — Q2 FY2021 | May 18, 2021 | — | $0.38 | $0.40 | +5.00% |
| — Q4 FY2020 | Dec 31, 2020 | — | $0.18 | $0.21 | +15.99% |
| — Q4 FY2020 | Nov 16, 2020 | — | $0.25 | $0.24 | -4.00% |
| — Q3 FY2020 | Aug 14, 2020 | — | $0.29 | $0.29 | -1.30% |
| — Q1 FY2020 | Mar 30, 2020 | — | $0.22 | $0.31 | +43.26% |
Q4 FY2021-0.79%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$0.50
Price After
$0.50
Q4 FY2021-0.46%
Report Date
Nov 15, 2021
EPS Beat/Miss
—
Price Before
$0.56
Price After
$0.56
Q3 FY2021-6.24%
Report Date
Aug 16, 2021
EPS Beat/Miss
—
Price Before
$0.64
Price After
$0.60
Q2 FY2021+5.00%
Report Date
May 18, 2021
EPS Beat/Miss
—
Price Before
$0.38
Price After
$0.40
Q4 FY2020+15.99%
Report Date
Dec 31, 2020
EPS Beat/Miss
—
Price Before
$0.18
Price After
$0.21
Q4 FY2020-4.00%
Report Date
Nov 16, 2020
EPS Beat/Miss
—
Price Before
$0.25
Price After
$0.24
Q3 FY2020-1.30%
Report Date
Aug 14, 2020
EPS Beat/Miss
—
Price Before
$0.29
Price After
$0.29
Q1 FY2020+43.26%
Report Date
Mar 30, 2020
EPS Beat/Miss
—
Price Before
$0.22
Price After
$0.31
Beat Rate0 / 8 quarters
Largest Move+43.26% (Q1 FY2020)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ACUR ends December
Acura Pharmaceuticals, Inc. (ACUR) most recently reported earnings on December 31, 2021 for Q4 FY2021, posting EPS of $0.00 (in line with the analyst consensus of —). The next ACUR earnings date is expected around September 1, 2026.
Each quarter, investors track ACUR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ACUR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ACUR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ACUR earnings · 4 questionsAcura Pharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. ACUR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ACUR historically reports after market close (AMC).
ACUR earnings datewhen is ACUR earningsACUR next earnings datewhen does ACUR report earningsACUR earnings calendar
▸ Source: FMP · Acura Pharmaceuticals, Inc. SEC filings · US GAAP · Acura Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026